Clear All
716 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
NA Metoclopramide Reglan 5mg, 10mg Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Yes 1991 In Use
NA Midostaurin Rydapt 25 mg Chemotherapy Tyrosine Kinase Inhibitor FLT3 Yes 2017 In Use
NA isotretinoin Absorica, Amnesteem, Claravis, Myorisan, Zenatane many Hormonal Therapy Immunomodulator Retinoic Acid Derivative Yes 1982 In Use
NA Tazemetostat Tazverik 200mg Chemotherapy Enzyme Inhibitor EZH2 Yes 2020 In Use
NA Sunitinib malate Sutent 25 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FLT, PDGFR,KIT, RET, CSF Yes 2006 In Use
NA Mitotane Lysodren unspecified Chemotherapy Miscellaneous Agent Adrenal Suppressant Yes 1970 In Use
Mobocertinib Exkivity 40mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2021 In Use
Momelotinib Ojjaara Multiple Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2023 In Use
NA Dasatinib Sprycel 140 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
NA Dasatinib Sprycel 70 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
NA lenvatinib Lenvima 10 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR,KIT,RET Yes 2015 In Use
NA lenvatinib Lenvima 4 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR,KIT,RET Yes 2015 In Use
NA Naldemedine Symproic 0.2mg Ancillary Therapy Opioid Antagonist Yes 2018 In Use
NA Dasatinib Sprycel 20 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
NA Dasatinib Sprycel 50 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
NA Dacomitinib Vizimpro 15mg, 30mg, 45mg Chemotherapy Tyrosine Kinase Inhibitor EGFR Yes 2018 In Use
NA Neratinib Nerlynx 40 mg Chemotherapy Tyrosine Kinase Inhibitor EGFR/HER2 Yes 2017 In Use
NA idelalisib Zydelig 100 mg Chemotherapy Enzyme Inhibitor PI3K Yes 2014 In Use
NA Nilotinib Tasigna 200 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2007 In Use
NA Nilotinib Tasigna 150 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2007 In Use
NA Vismodegib Vismodegib 150 mg Chemotherapy Hedgehog Pathway Inhibitor SMO Yes 2012 In Use
Futibatinib Lytgobi 4mg Chemotherapy Tyrosine Kinase Inhibitor FGFR Yes 2023 In Use
NA Gardasil Human papillomavirus vaccine Ancillary Therapy Protective Agent HPV Vaccine No 2006 2016 In Use
NA Nilutamide Anadron, Nilandron 150 mg Hormonal Therapy Androgen Receptor Inhibitor Yes 1996 In Use
NA Nintedanib Ofev 150 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, FLT3 Yes 2014 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.